Pegvaliase

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Phenylketonurias

Conditions

Phenylketonurias

Trial Timeline

Jan 17, 2019 → Dec 31, 2020

NCT ID

NCT03792451

About Pegvaliase

Pegvaliase is a pre-clinical stage product being developed by BioMarin Pharmaceutical for Phenylketonurias. The current trial status is completed. This product is registered under clinical trial identifier NCT03792451. Target conditions include Phenylketonurias.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06305234	Pre-clinical	Recruiting	Jan 20, 2024	Nov 18, 2033	Phenylketonuria (PKU)
NCT05579548	Pre-clinical	Recruiting	Nov 22, 2022	Oct 4, 2032	Phenylketonuria, Maternal
NCT05270837	Phase 3	Active	Jun 17, 2022	Oct 1, 2027	Phenylketonuria (PKU)
NCT05813678	Pre-clinical	Recruiting	Jun 6, 2022	Nov 1, 2033	Phenylketonuria (PKU)
NCT03792451	Pre-clinical	Completed	Jan 17, 2019	Dec 31, 2020	Phenylketonurias
NCT03694353	Phase 3	Completed	Sep 13, 2018	Jan 13, 2021	Phenylketonuria (PKU)

Competing Products

7 competing products in Phenylketonurias

See all competitors

Product	Company	Stage	Hype Score
Sapropterin	BioMarin Pharmaceutical	Pre-clinical	20
sapropterin dihydrochloride	BioMarin Pharmaceutical	Phase 2	49
sapropterin dihydrochloride	BioMarin Pharmaceutical	Phase 3	74
sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin	BioMarin Pharmaceutical	Phase 3	74
Pegvaliase-Pqpz	BioMarin Pharmaceutical	Pre-clinical	20
Palynziq	BioMarin Pharmaceutical	Pre-clinical	20
Sapropterin Dihydrochloride + Placebo	BioMarin Pharmaceutical	Phase 3	74

Other Products from BioMarin Pharmaceutical

NaglazymeApproved

saproterin dihydrochlorideApproved

Pegvaliase + MethotrexateApproved

Kuvan®Approved

KuvanApproved